CHEMOSAT®, marketed by medac Pharma, is a minimally invasive delivery system for the administration of high-dose chemotherapy directly to the liver while controlling systemic exposure. CHEMOSAT® is used predominantly to treat patients with unresectable liver-dominant metastatic ocular melanoma.
Delcath Systems, Inc. (the manufacturers of CHEMOSAT®) will present new preliminary data from the Phase 3 FOCUS trial at the Annual ASCO Meeting next week.
“Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial” presented by Jonathan S. Zager, MD FACS is taking place on June 4, 9:00 AM (EDT) (2:00 PM in the UK).
Dr Zager will be presenting on behalf of the Principal Investigators that participated in the FOCUS trial.
FOCUS is an open label, single-arm, multi-centre trial, conducted in 23 centres in USA and EU sponsored by Delcath Systems, Inc. The trial is intended to evaluate the efficacy, safety and pharmacokinetics of melphalan hydrochloride in combination with CHEMOSAT® in patients with hepatic-dominant ocular melanoma. In the oral presentation at the ASCO Annual Meeting we are expecting new positive data regarding the prespecified endpoints overall response rate, median progression free survival and disease control rate.